NINDS and Santhera complete FRDA study
The US National Institute of Neurological Disorders and Stroke, part of the National Institutes of Health, and Swiss firm Santhera Pharmaceuticals say they have completed a Phase II trial of the developmental agent SNT-MC17/idebenone in the neurological disorder, Fredreich's Ataxia (FRDA).
The results showed that the agent was safe and well-tolerated, and indicated that it may cause an improvement in FRDA's neurological symptoms. Full data will be presented by the NINDS at the upcoming 3rd International Freidreich's Ataxia Scientific Conference to be held in Bathesda, Maryland, USA, next month.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze